BR-101801 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-101801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-101801 is under development for the treatment of relapsed/refractory B-cell lymphomas including mantle cell lymphoma, marginal zone lymphoma, Waldensian's macroglobulinemia, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, peripheral T-cell lymphomas and follicular lymphoma. It acts by targeting DNA activated protein kinase (DNA-PK), phosphatidylinositol 3 kinase delta (PI3Kdelta) and (PI3KGamma). It is administered through oral route.
Boryung Pharmaceutical overview
Boryung Pharmaceutical (Boryung) is a pharmaceutical company. it It offers product portfolio include Kanarb, Dukarb, Tuvero, TODULA, BESTO, and gelfosM. The company develops and manufactures over the counter and prescription drugs for the treatment of cancer, infections, and gene therapy. Its Kanarb drug used to treat hypertension and Gelfos, an antacid for the treatment of hypergastric acidity, gastritis and gastric fullness. The company’s pipeline products include BR1006, BR1007, BR1008 for treating hypertension; BR2002, a drug used to treat lymphoma; and BR8003, a vaccine designed for the treatment of Hepatitis A. Boryung is headquartered in Seoul, South Korea.
For a complete picture of BR-101801’s drug-specific PTSR and LoA scores, buy the report here.